Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILES: Moderate- vs High-Intensity Lipid-Lowering Therapy in Asymptomatic Intracranial Atherosclerotic Disease
NCT07791823Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
Randomised, open-label trial in intracranial atherosclerosis (ICAD) (2 arms). Primary endpoint: Incidence of composite cardiovascular events at 36 months. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
intracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT07791823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791823.